AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03689582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Positron Emission Tomography/Computed Tomography (PET/CT) imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi).
Study NCT00855959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
Study NCT00855959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Turbuhaler
Description: Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
Study NCT00003575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study NCT00003575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT03999515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT03999515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT03999515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT01742195 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oral EBUS insertion
Study NCT01742195 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal EBUS insertion
Study NCT02166099 — intervention group
Intervention type: PROCEDURE
Intervention: Choledochoscopy using Digital Spyglass
Description: Choledochoscopy using Digital Spyglass during Endoscopy
Study NCT00799682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: 0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
Study NCT00799682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan Z
Description: 0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
Study NCT01419795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT01419795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide
Description: Given PO
Study NCT01419795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01419795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01419795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT01419795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01419795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00769886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen/naphazoline
Description: One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
Study NCT00769886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen
Description: One drop of Ketotifen in study eye at visit 3 and visit 4.
Study NCT00769886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naphazoline
Description: One drop of naphazoline in study eye at vist 3 and visit 4.
Study NCT00769886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop of vehicle in study eye at visit 3 and visit 4.
Study NCT00060645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
Study NCT01790594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
Study NCT01790594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT01790594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study NCT01790594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte Globulin (Rabbit)
Study NCT01790594 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte Globulin (Rabbit)
Study NCT01790594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: There may be an opportunity to withdraw tacrolimus at week 40
Study NCT01790594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: There may be an opportunity to withdraw tacrolimus at week 40
Study NCT01790594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Study NCT01790594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Study NCT02155634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
Study NCT01288755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: One 25 mg tablet, once daily, for 11 days (TrtA and C)
Study NCT01288755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
Study NCT03006146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
Study NCT03016312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT03016312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
Study NCT03016312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
Study NCT03036410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: standard telephone setting
Description: without streaming function
Study NCT03036410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DECT
Description: cordless telephone (streaming to both hearing devices)
Study NCT03036410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EasyCall
Description: accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
Study NCT03036410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DuoPhone
Description: streaming function, which provides the speech signal to both ears
Study NCT01089686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venoplasty
Description: Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
Study NCT01089686 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure (non-treatment)
Description: Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
Study NCT03880292 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Document intraoperative Maneuvers
Description: Monitoring procedure during surgery
Study NCT02632292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb GT1
Description: Bioresorbable vascular scaffold
Study NCT02632292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus
Description: Everolimus-eluting stent
Study NCT02721667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
Study NCT02721667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
Study NCT05729971 — intervention group
Intervention type: PROCEDURE
Intervention: nasogastric tube
Description: The intervention consists in removing or not the nasogastric tube at the end of the surgery.
Study NCT03268525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.5 % Injectable Solution
Description: Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
Study NCT03268525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Local infiltration by Sodium Chloride 0.9% prior to incision
Study NCT04247087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phytomenadione
Description: phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
Study NCT04247087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: 1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
Study NCT02750982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
Study NCT03568396 — intervention group
Intervention type: DEVICE
Intervention: Pupillometer
Description: Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.
Study NCT01046773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
Study NCT01046773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
Study NCT04081623 — intervention group
Intervention type: DEVICE
Intervention: Raydiant Oximetry Sensing System
Description: The investigational device is used to record fetal pulse signals.
Study NCT01375231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measured Resection of patellofemoral joint
Description: The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
Study NCT01375231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measured resection of patella
Description: The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
Study NCT02960750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A workplace sit less and move more web-based program for Spanish office employees
Description: W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
Study NCT02960750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparison group
Description: The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
Study NCT02645227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by OFD for treating bone defect
Study NCT02645227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Oral prophylaxis followed by OFD with PRF placement into the bone defect
Study NCT02645227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with PRF and 1.2% Rosuvastatin
Description: Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
Study NCT02224690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 20 mg/kg/day Dose
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT02224690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT04638595 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
Study NCT01383460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)
Description: G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
Study NCT01383460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study NCT01911611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870868
Description: Single ascending doses
Study NCT01911611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single ascending doses
Study NCT02876822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01590979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: 1000mg, two times a day, 12 hour intervals
Study NCT01590979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two times a day, 12 hour intervals
Study NCT03148535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: bipolar depression recieve lithium Carbonate treatment
Study NCT00950274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD133+ autologous bone marrow stem cell
Description: Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
Study NCT03148535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate combined with SSRI antidepressant treatment
Description: lithium carbonate combined with SSRI antidepressant treatment
Study NCT01855412 — intervention group
Intervention type: OTHER
Intervention: PAD endovascular treatments
Description: All FDA-cleared endovascular PAD treatments
Study NCT01329263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol to non-menthol
Description: Switch from smoking menthol to non-menthol cigarettes.
Study NCT00950274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
Study NCT00851838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
Study NCT00665665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
Study NCT00665665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for s.c. injection
Study NCT00665665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
Study NCT00665665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
Study NCT00665665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0182
Description: 60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
Study NCT01631435 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pillcam colon capsule and PillCam™ Prep Procedure
Description: PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
Study NCT01631435 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ileocolonoscopy
Description: Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum
Study NCT02122679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT02122679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03007966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal / Iliohypogastric Block
Description: Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
Study NCT03007966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.